Human antibodies for novel targets and underserved diseases.
ArGEN-X focuses on the discovery and development of human antibodies using its proprietary SIMPLE Antibody (TM) platform. The platform generates a limitless source of extremely high quality human antibodies that modulate the function of disease targets, including complex receptors and highly conserved targets, that are not possible to generate with other antibody technologies. The Lead antibodies generated are further differentiated through enhancement of their cell killing properties (Potelligent® technology) and circulation time in the body (NHance™ technology). arGEN-X’s portfolio consists of novel programs addressing oncology, autoimmune and inflammation indications.
- CEO Tim van Hauwermeiren, MSc, EMBA
- Industry Biotech